Aratana Therapeutics (PETX) Given a $10.00 Price Target by HC Wainwright Analysts

Aratana Therapeutics (NASDAQ:PETX) has been given a $10.00 target price by HC Wainwright in a research report issued on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 152.53% from the stock’s current price.

A number of other research analysts have also issued reports on the company. Credit Suisse Group reissued an “outperform” rating and issued a $8.00 target price (down previously from $9.00) on shares of Aratana Therapeutics in a report on Friday, March 16th. CL King raised Aratana Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Monday, March 12th. They noted that the move was a valuation call. Zacks Investment Research raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $6.00 target price on shares of Aratana Therapeutics in a report on Monday, December 18th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Aratana Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.39.

How to Become a New Pot Stock Millionaire

Aratana Therapeutics stock opened at $3.96 on Monday. The stock has a market capitalization of $185.25, a P/E ratio of -3.36 and a beta of 3.13. The company has a quick ratio of 2.02, a current ratio of 2.40 and a debt-to-equity ratio of 0.24. Aratana Therapeutics has a twelve month low of $3.67 and a twelve month high of $7.67.

In related news, insider Craig A. Tooman sold 30,000 shares of Aratana Therapeutics stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total value of $158,100.00. Following the sale, the insider now directly owns 75,024 shares in the company, valued at $395,376.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Peter Steven St sold 19,367 shares of Aratana Therapeutics stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total value of $92,380.59. Following the completion of the sale, the chief executive officer now owns 672,259 shares in the company, valued at $3,206,675.43. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC purchased a new stake in Aratana Therapeutics during the fourth quarter worth $110,000. Voya Investment Management LLC boosted its position in Aratana Therapeutics by 22.7% during the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 3,610 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Aratana Therapeutics by 6.6% during the second quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 1,875 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Aratana Therapeutics by 25.3% during the second quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 6,898 shares in the last quarter. Finally, Ellington Management Group LLC purchased a new stake in Aratana Therapeutics during the fourth quarter worth $304,000. Hedge funds and other institutional investors own 71.07% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Aratana Therapeutics (PETX) Given a $10.00 Price Target by HC Wainwright Analysts” was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.thestockobserver.com/2018/03/21/aratana-therapeutics-petx-given-a-10-00-price-target-by-hc-wainwright-analysts.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply